How do you distinguish PBC activity from MASLD-related signal when ALP is only modestly elevated (about 1.2–1.5× ULN) and liver stiffness may be confounded?
How does that affect your decision to add PBC-directed second-line therapy versus prioritizing metabolic intervention?